West Pharmaceutical Services, Inc. has seen its stock prices drop significantly over the past year, lagging behind the broader market and sector. However, after releasing better-than-expected Q3 results, the stock soared 10.9% in a single trading session. The company reported a 7.7% increase in net sales and a 5.9% rise in adjusted EPS. Analysts expect an adjusted EPS of $7.07 for the full fiscal year, with a solid earnings surprise history. Consensus among analysts is a “Strong Buy,” with a mean price target of $350, representing a 35.8% premium to current levels.

Read more at Barchart: What Are Wall Street Analysts’ Target Price for West Pharmaceutical Services Stock?